Sign in

Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer

By B. Press and others at
LogoFred Hutchinson Cancer Research Center
and
LogoUniversity of Washington
BackgroundAlthough the Decipher genomic classifier has been validated as a prognostic tool for several prostate cancer endpoints, little is known about its role in assessing risks of biopsy reclassification among patients on active surveillance, a key event that often triggers treatment ObjectiveTo evaluate the association between Decipher genomic classifier and biopsy... Show more
February 11, 2022
=
0
Loading PDF…
Loading full text...
Similar articles
Loading recommendations...
=
0
x1
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
Click on play to start listening